Document is current
Any future updates will be listed below
-
Authors
Kincaid, John W. R. https://orcid.org/0000-0003-0660-9813
Rimmington, Debra https://orcid.org/0000-0002-3715-3970
Tadross, John A. https://orcid.org/0000-0002-8424-1252
Cimino, Irene https://orcid.org/0000-0003-1397-5408
Zvetkova, Ilona https://orcid.org/0000-0003-4356-0086
Kaser, Arthur https://orcid.org/0000-0003-1419-3344
Richards, Paul
Patel, Satish https://orcid.org/0000-0002-5345-8942
O’Rahilly, Stephen https://orcid.org/0000-0003-2199-4449
Coll, Anthony P. https://orcid.org/0000-0003-2594-7463
-
Funding
Funding for this research was provided by:
Medical Research Council Metabolic Diseases Unit Disease Model Core (MC_UU_00014/5)
MRC Metabolic Diseases Unit (MC_UU_00014/1)
NIHR Clinical Lectureship (CL-2019-14-504)
- License Information
-
More Information
Article History
Received: 23 November 2023
Accepted: 10 January 2024
First Online: 22 January 2024
Competing interests
: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: P.R. is an advisor and shareholder in Kallyope, Inc. S.O. undertakes remunerated consultancy work for Pfizer, AstraZeneca, Third Rock Ventures, Courage Therapeutics, Northsea Therapeutics, and LG Chem Life Sciences. I.C., S.O., and A.P.C. have filed a patent on therapeutic targeting of GDF15-GFRAL.
